KalVista Pharmaceuticals (KALV) Operating Margin (2014 - 2025)

KalVista Pharmaceuticals (KALV) reported Operating Margin of 118.02% for Q3 2025, up 76.41% sequentially from 500.27% in Q2 2025.

KalVista Pharmaceuticals (KALV) Operating Margin (2014 - 2025) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 8 years of Operating Margin data on file, last reported at 118.02% in Q3 2025.

For the quarter ending Q3 2025, Operating Margin changed N/A year-over-year to 118.02%; the trailing twelve-month figure through Jul 2025 stood at 314.8% (up 135420.0% YoY), and the FY2025 full-year result was 1709.05%, down 142816.0% from the prior year.
Operating Margin rose to 118.02% in Q3 2025, from 500.27% in the prior quarter.
In the past five years, Operating Margin ranged from a high of 118.02% in Q3 2025 to a low of 500.27% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	KalVista Pharmaceuticals	1.36 Bn	1.36 Bn	49.41 Mn	-118.02%

Download Data